<div id="readability-page-1">The latest announcement is out from Nektar Therapeutics ( (NKTR) ).At Nektar Therapeutics’ Annual Meeting of Stockholders held on June 4, 2026, stockholders elected Howard W. Robin to the board of directors to serve until the 2029 Annual Meeting, while existing directors Jeffrey Ajer, Diana Brainard, Robert Chess, R. Scott Greer, and Roy Whitfield continued their service. Shareholders also approved an amendment to the 2017 Performance Incentive Plan to add 3,000,000 shares for equity awards, ratified Ernst &amp; Young LLP as the independent auditor for the 2026 fiscal year, and endorsed the non-binding advisory resolution on executive compensation, reinforcing the company’s current leadership, compensation framework, and governance structure. The most recent analyst rating on (NKTR) stock is a Buy with a $151.00 price target. To see the full list of analyst forecasts on Nektar Therapeutics stock, see the NKTR Stock Forecast page. <div> Spark’s Take on NKTR Stock According to Spark, TipRanks’ AI Analyst, NKTR is a Neutral. The score is held back primarily by weak financial performance (large losses and heavy cash burn) and bearish technicals. These are partially offset by a constructive earnings call with strong clinical progress, defined Phase III plans, and improved liquidity/cash runway; valuation offers limited support due to negative earnings and no dividend. To see Spark’s full report on NKTR stock, click here. </div><div> More about Nektar Therapeutics Nektar Therapeutics is a Delaware-incorporated biopharmaceutical company focused on developing therapeutics, operating under a public company structure with a board of directors and typical governance practices. Its market activity is shaped by stockholder oversight, equity incentive programs, and engagement with independent auditors to support its research-driven operations. Average Trading Volume: 1,006,397 Technical Sentiment Signal: Sell Current Market Cap: $2B </div><div> Learn more about NKTR stock on TipRanks’ Stock Analysis page. </div></div>

NKTR

Nektar Therapeutics stockholders approved governance changes, including electing Howard W. Robin to the board and amending the 2017 Performance Incentive Plan to add 3 million shares. They also ratified Ernst & Young as auditor and endorsed executive compensation. While analysts rate the stock a Buy with a $151 target, Spark AI rates it Neutral due to weak financials, though clinical progress offers some support.

Nektar Stockholders Approve Governance and Incentive Plan Changes